Abstract：
Cardiovascular agents commonly used in geriatric patients, are linked to potentially avoidable harm and might hence be a suitable substrate for medication review practices. Therefore, we sought to update and validate the content of the cardiovascular segment of the previously published Rationalization of Home Medication by an Adjusted STOPP list in Older Patients (RASP) List.
A three-step study was conducted by the pharmacy department in collaboration with the geriatric medicine and cardiology department at the University Hospitals Leuven, Belgium. First, the cardiovascular segment of the RASP list version 2014 was updated taking into account published research, other screening tools and the input of end-users. Secondly, this draft was reviewed during three panel discussions with five expert cardiologists and three clinical pharmacists, all of whom had relevant expertise in geriatric pharmacotherapy. Thirdly, the content was validated using a modified Delphi Technique by a panel of European hospital pharmacists, cardiologists, geriatricians and an internal medicine physician.
After the first and second step, the RASP_CARDIO list comprised 94 statements. Consensus (≥ 80% agreement) of all statements and one new statement about gliflozins in heart failure was achieved by a panel of seventeen experts across four European countries after two validation rounds. The final construct comprised a list of 95 statements related to potentially inappropriate prescribing of cardiovascular agents.
The RASP_CARDIO list is an updated and validated explicit screening tool to optimize cardiovascular pharmacotherapy in geriatric patients.
A three-step study was conducted by the pharmacy department in collaboration with the geriatric medicine and cardiology department at the University Hospitals Leuven, Belgium. First, the cardiovascular segment of the RASP list version 2014 was updated taking into account published research, other screening tools and the input of end-users. Secondly, this draft was reviewed during three panel discussions with five expert cardiologists and three clinical pharmacists, all of whom had relevant expertise in geriatric pharmacotherapy. Thirdly, the content was validated using a modified Delphi Technique by a panel of European hospital pharmacists, cardiologists, geriatricians and an internal medicine physician.
After the first and second step, the RASP_CARDIO list comprised 94 statements. Consensus (≥ 80% agreement) of all statements and one new statement about gliflozins in heart failure was achieved by a panel of seventeen experts across four European countries after two validation rounds. The final construct comprised a list of 95 statements related to potentially inappropriate prescribing of cardiovascular agents.
The RASP_CARDIO list is an updated and validated explicit screening tool to optimize cardiovascular pharmacotherapy in geriatric patients.
摘要：
老年患者常用的心血管药物，与潜在可避免的伤害有关，因此可能是药物审查实践的合适基质。因此,我们试图通过调整后的老年患者STOPP列表(RASP)来更新和验证先前发表的家庭用药合理化的心血管部分内容.
药学部门与鲁汶大学医院的老年医学和心脏病学部门合作进行了一项三步研究，比利时。首先,2014年RASP列表版本的心血管部分进行了更新，考虑到已发表的研究，其他筛选工具和最终用户的输入。其次,在与五名心脏病专家和三名临床药剂师进行的三次小组讨论中，审查了该草案，他们都有老年药物治疗的相关专业知识.第三，内容由欧洲医院药剂师小组使用改良的Delphi技术进行验证，心脏病学家,老年病医生和内科医师。
在第一步和第二步之后，RASP_CARDIO列表包含94个语句。经过两轮验证，四个欧洲国家的十七名专家组成的小组达成了所有关于格利福净在心力衰竭中的共识（≥80％同意）和一项新声明。最终的结构包括95个与潜在的不适当的心血管药物处方有关的陈述。
RASP_CARDIO列表是一种更新和验证的明确筛查工具，用于优化老年患者的心血管药物治疗。
药学部门与鲁汶大学医院的老年医学和心脏病学部门合作进行了一项三步研究，比利时。首先,2014年RASP列表版本的心血管部分进行了更新，考虑到已发表的研究，其他筛选工具和最终用户的输入。其次,在与五名心脏病专家和三名临床药剂师进行的三次小组讨论中，审查了该草案，他们都有老年药物治疗的相关专业知识.第三，内容由欧洲医院药剂师小组使用改良的Delphi技术进行验证，心脏病学家,老年病医生和内科医师。
在第一步和第二步之后，RASP_CARDIO列表包含94个语句。经过两轮验证，四个欧洲国家的十七名专家组成的小组达成了所有关于格利福净在心力衰竭中的共识（≥80％同意）和一项新声明。最终的结构包括95个与潜在的不适当的心血管药物处方有关的陈述。
RASP_CARDIO列表是一种更新和验证的明确筛查工具，用于优化老年患者的心血管药物治疗。
